Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease

Salvatore Petta, Luca Valenti, Gianluca Svegliati-Baroni, Massimiliano Ruscica, Rosaria Maria Pipitone, Paola Dongiovanni, Chiara Rychlicki, Nicola Ferri, Calogero Cammà, Anna Ludovica Fracanzani, Irene Pierantonelli, Vito Di Marco, Marica Meroni, Debora Giordano, Stefania Grimaudo, Marco Maggioni, Daniela Cabibi, Silvia Fargion, Antonio Craxì

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Context: Contrasting data have been reported on the role of irisin, a novel myokine encoded by the fibronectin type III domain-containing protein 5 (FNDC5) gene, in nonalcoholic fatty liver disease (NAFLD) pathogenesis. We tested in patients with suspected nonalcoholic steatohepatitis (NASH) the association of FNDC5 variants, hepatic expression, and circulating irisin with liver damage (F2 to F4 fibrosis as main outcome). We also investigated whether irisin modulates hepatocellular fat accumulation and stellate cell activation in experimental models. Methods: We considered 593 consecutive patients who underwent liver biopsy for suspected NASH and 192 patients with normal liver enzymes and without steatosis. FNDC5 rs3480 and rs726344 genotypes were assessed by 50 nuclease assays. Hepatic irisin expression was evaluated in mice fed a high-fat diet or treated with CCl4. The effect of irisin was evaluated in fat-laden HepG2 hepatocytes and in hepatic stellate cells (HSCs). Results: In patients at risk for NASH [odds ratio (OR) = 0.64, 95% confidence interval (CI), 0.47 to 0.87; P = 0.005], and more so in the high-risk subgroup of those with impaired fasting glucose/diabetes (OR = 0.44, 95% CI, 0.26 to 0.74; P = 0.002), the rs3480 A.G variant was independently associated with protection from F2 to F4 fibrosis. Irisin is expressed in human activated HSC, where it mediated fibrogenic actions and collagen synthesis, and is overexpressed in NAFLD patients with F2 to F4 fibrosis and CCl4-treated mice. However, Irisin does not affect fat accumulation in HepG2 and is not induced by high-fat-diet-inducing NAFLD. Conclusions: The FNDC5 rs3480 variant is associatedwith protection fromclinically significant fibrosis in patients with NAFLD, while irisin expression is correlated with the severity of NAFLD and may be involved in extracellular matrix deposition. These data suggest that irisin is involved in regulation of hepatic fibrogenesis.

Original languageEnglish
Pages (from-to)2660-2669
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume102
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Polymorphism
Fibronectins
Liver Cirrhosis
Liver
Fats
Proteins
Fibrosis
Hepatic Stellate Cells
High Fat Diet
Nutrition
Odds Ratio
Confidence Intervals
Non-alcoholic Fatty Liver Disease
Fibronectin Type III Domain
Biopsy
Medical problems
Extracellular Matrix
Hepatocytes
Assays
Fasting

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease. / Petta, Salvatore; Valenti, Luca; Svegliati-Baroni, Gianluca; Ruscica, Massimiliano; Pipitone, Rosaria Maria; Dongiovanni, Paola; Rychlicki, Chiara; Ferri, Nicola; Cammà, Calogero; Fracanzani, Anna Ludovica; Pierantonelli, Irene; Di Marco, Vito; Meroni, Marica; Giordano, Debora; Grimaudo, Stefania; Maggioni, Marco; Cabibi, Daniela; Fargion, Silvia; Craxì, Antonio.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 102, No. 8, 01.08.2017, p. 2660-2669.

Research output: Contribution to journalArticle

Petta, S, Valenti, L, Svegliati-Baroni, G, Ruscica, M, Pipitone, RM, Dongiovanni, P, Rychlicki, C, Ferri, N, Cammà, C, Fracanzani, AL, Pierantonelli, I, Di Marco, V, Meroni, M, Giordano, D, Grimaudo, S, Maggioni, M, Cabibi, D, Fargion, S & Craxì, A 2017, 'Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease', Journal of Clinical Endocrinology and Metabolism, vol. 102, no. 8, pp. 2660-2669. https://doi.org/10.1210/jc.2017-00056
Petta, Salvatore ; Valenti, Luca ; Svegliati-Baroni, Gianluca ; Ruscica, Massimiliano ; Pipitone, Rosaria Maria ; Dongiovanni, Paola ; Rychlicki, Chiara ; Ferri, Nicola ; Cammà, Calogero ; Fracanzani, Anna Ludovica ; Pierantonelli, Irene ; Di Marco, Vito ; Meroni, Marica ; Giordano, Debora ; Grimaudo, Stefania ; Maggioni, Marco ; Cabibi, Daniela ; Fargion, Silvia ; Craxì, Antonio. / Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease. In: Journal of Clinical Endocrinology and Metabolism. 2017 ; Vol. 102, No. 8. pp. 2660-2669.
@article{0ebc148694654677b900d68501fb9317,
title = "Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease",
abstract = "Context: Contrasting data have been reported on the role of irisin, a novel myokine encoded by the fibronectin type III domain-containing protein 5 (FNDC5) gene, in nonalcoholic fatty liver disease (NAFLD) pathogenesis. We tested in patients with suspected nonalcoholic steatohepatitis (NASH) the association of FNDC5 variants, hepatic expression, and circulating irisin with liver damage (F2 to F4 fibrosis as main outcome). We also investigated whether irisin modulates hepatocellular fat accumulation and stellate cell activation in experimental models. Methods: We considered 593 consecutive patients who underwent liver biopsy for suspected NASH and 192 patients with normal liver enzymes and without steatosis. FNDC5 rs3480 and rs726344 genotypes were assessed by 50 nuclease assays. Hepatic irisin expression was evaluated in mice fed a high-fat diet or treated with CCl4. The effect of irisin was evaluated in fat-laden HepG2 hepatocytes and in hepatic stellate cells (HSCs). Results: In patients at risk for NASH [odds ratio (OR) = 0.64, 95{\%} confidence interval (CI), 0.47 to 0.87; P = 0.005], and more so in the high-risk subgroup of those with impaired fasting glucose/diabetes (OR = 0.44, 95{\%} CI, 0.26 to 0.74; P = 0.002), the rs3480 A.G variant was independently associated with protection from F2 to F4 fibrosis. Irisin is expressed in human activated HSC, where it mediated fibrogenic actions and collagen synthesis, and is overexpressed in NAFLD patients with F2 to F4 fibrosis and CCl4-treated mice. However, Irisin does not affect fat accumulation in HepG2 and is not induced by high-fat-diet-inducing NAFLD. Conclusions: The FNDC5 rs3480 variant is associatedwith protection fromclinically significant fibrosis in patients with NAFLD, while irisin expression is correlated with the severity of NAFLD and may be involved in extracellular matrix deposition. These data suggest that irisin is involved in regulation of hepatic fibrogenesis.",
author = "Salvatore Petta and Luca Valenti and Gianluca Svegliati-Baroni and Massimiliano Ruscica and Pipitone, {Rosaria Maria} and Paola Dongiovanni and Chiara Rychlicki and Nicola Ferri and Calogero Camm{\`a} and Fracanzani, {Anna Ludovica} and Irene Pierantonelli and {Di Marco}, Vito and Marica Meroni and Debora Giordano and Stefania Grimaudo and Marco Maggioni and Daniela Cabibi and Silvia Fargion and Antonio Crax{\`i}",
year = "2017",
month = "8",
day = "1",
doi = "10.1210/jc.2017-00056",
language = "English",
volume = "102",
pages = "2660--2669",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with nonalcoholic fatty liver disease

AU - Petta, Salvatore

AU - Valenti, Luca

AU - Svegliati-Baroni, Gianluca

AU - Ruscica, Massimiliano

AU - Pipitone, Rosaria Maria

AU - Dongiovanni, Paola

AU - Rychlicki, Chiara

AU - Ferri, Nicola

AU - Cammà, Calogero

AU - Fracanzani, Anna Ludovica

AU - Pierantonelli, Irene

AU - Di Marco, Vito

AU - Meroni, Marica

AU - Giordano, Debora

AU - Grimaudo, Stefania

AU - Maggioni, Marco

AU - Cabibi, Daniela

AU - Fargion, Silvia

AU - Craxì, Antonio

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Context: Contrasting data have been reported on the role of irisin, a novel myokine encoded by the fibronectin type III domain-containing protein 5 (FNDC5) gene, in nonalcoholic fatty liver disease (NAFLD) pathogenesis. We tested in patients with suspected nonalcoholic steatohepatitis (NASH) the association of FNDC5 variants, hepatic expression, and circulating irisin with liver damage (F2 to F4 fibrosis as main outcome). We also investigated whether irisin modulates hepatocellular fat accumulation and stellate cell activation in experimental models. Methods: We considered 593 consecutive patients who underwent liver biopsy for suspected NASH and 192 patients with normal liver enzymes and without steatosis. FNDC5 rs3480 and rs726344 genotypes were assessed by 50 nuclease assays. Hepatic irisin expression was evaluated in mice fed a high-fat diet or treated with CCl4. The effect of irisin was evaluated in fat-laden HepG2 hepatocytes and in hepatic stellate cells (HSCs). Results: In patients at risk for NASH [odds ratio (OR) = 0.64, 95% confidence interval (CI), 0.47 to 0.87; P = 0.005], and more so in the high-risk subgroup of those with impaired fasting glucose/diabetes (OR = 0.44, 95% CI, 0.26 to 0.74; P = 0.002), the rs3480 A.G variant was independently associated with protection from F2 to F4 fibrosis. Irisin is expressed in human activated HSC, where it mediated fibrogenic actions and collagen synthesis, and is overexpressed in NAFLD patients with F2 to F4 fibrosis and CCl4-treated mice. However, Irisin does not affect fat accumulation in HepG2 and is not induced by high-fat-diet-inducing NAFLD. Conclusions: The FNDC5 rs3480 variant is associatedwith protection fromclinically significant fibrosis in patients with NAFLD, while irisin expression is correlated with the severity of NAFLD and may be involved in extracellular matrix deposition. These data suggest that irisin is involved in regulation of hepatic fibrogenesis.

AB - Context: Contrasting data have been reported on the role of irisin, a novel myokine encoded by the fibronectin type III domain-containing protein 5 (FNDC5) gene, in nonalcoholic fatty liver disease (NAFLD) pathogenesis. We tested in patients with suspected nonalcoholic steatohepatitis (NASH) the association of FNDC5 variants, hepatic expression, and circulating irisin with liver damage (F2 to F4 fibrosis as main outcome). We also investigated whether irisin modulates hepatocellular fat accumulation and stellate cell activation in experimental models. Methods: We considered 593 consecutive patients who underwent liver biopsy for suspected NASH and 192 patients with normal liver enzymes and without steatosis. FNDC5 rs3480 and rs726344 genotypes were assessed by 50 nuclease assays. Hepatic irisin expression was evaluated in mice fed a high-fat diet or treated with CCl4. The effect of irisin was evaluated in fat-laden HepG2 hepatocytes and in hepatic stellate cells (HSCs). Results: In patients at risk for NASH [odds ratio (OR) = 0.64, 95% confidence interval (CI), 0.47 to 0.87; P = 0.005], and more so in the high-risk subgroup of those with impaired fasting glucose/diabetes (OR = 0.44, 95% CI, 0.26 to 0.74; P = 0.002), the rs3480 A.G variant was independently associated with protection from F2 to F4 fibrosis. Irisin is expressed in human activated HSC, where it mediated fibrogenic actions and collagen synthesis, and is overexpressed in NAFLD patients with F2 to F4 fibrosis and CCl4-treated mice. However, Irisin does not affect fat accumulation in HepG2 and is not induced by high-fat-diet-inducing NAFLD. Conclusions: The FNDC5 rs3480 variant is associatedwith protection fromclinically significant fibrosis in patients with NAFLD, while irisin expression is correlated with the severity of NAFLD and may be involved in extracellular matrix deposition. These data suggest that irisin is involved in regulation of hepatic fibrogenesis.

UR - http://www.scopus.com/inward/record.url?scp=85026908520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026908520&partnerID=8YFLogxK

U2 - 10.1210/jc.2017-00056

DO - 10.1210/jc.2017-00056

M3 - Article

AN - SCOPUS:85026908520

VL - 102

SP - 2660

EP - 2669

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -